US5380646A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Thrombus detection using radiolabelled disintegrins
Assignee: Temple University
•
Filing: 1992-10-19
•
Granted: 1995-01-10
•
Expires: 2012-10-19
Abstract
Abstract Radiolabelled polypeptides derived from the Viperidae disintegrins are provided as well as a method for the detection of venous and arterial thrombi, pulmonary emboli and tumors or abscesses that have a thrombus component. Compositions suitable for parenteral administration comprising the radiolabelled polypeptides and a pharmaceutically acceptable carrier are also provided.
Inventors
- 👤 Linda C. Knight
- 👤 Alan H. Maurer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 23:50
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; A61K2123/00
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
135 words
A method for detecting venous thrombi, arterial thrombi, pulmonary emboli, or tumors or abscesses having a thrombus component, comprising: (a) administering to a patient at least one radiolabelled polypeptide having a native disintegrin amino acid sequence from about 40 to about 90 amino acids in length, said radiolabelled polypeptide having a thrombus-to-blood ratio of at least about 4:1 and containing the segment -Arg-Gly-Asp-, wherein the glycine residue of said segment is designated as position zero of said radiolabelled polypeptide, said radiolabelled polypeptide further comprising cysteine amino acid residues at positions -23, -18, -17, -14, -5, +7, and +14, relative to said glycine residue, and said radiolabelled polypeptide further comprising the following amino acid residues occurring at the following positions: Gly (-20), Phe (-12), Asp (+4), and Pro (+15); and (b) scintigraphically imaging the radiolabelled polypeptides.
Claim 2
Independent Claim
135 words
A method for detecting venous thrombi, arterial thrombi, pulmonary emboli, or tumors or abscesses having a thrombus component, comprising: (a) administering to a patient at least one radiolabelled polypeptide having a native disintegrin amino acid sequence from about 40 to about 90 amino acids in length, said radiolabelled polypeptide having a thrombus-to-blood ratio of at least about 4:1 and containing the segment -Arg-Gly-Asp-, wherein the glycine residue of said segment is designated as position zero of said radiolabelled polypeptide, said radiolabelled polypeptide further comprising cysteine amino acid residues at positions -23, -18, -17, -14, -5, +7, and +14, relative to said glycine residue, and said radiolabelled polypeptide further comprising the following amino acid residues occurring at the following positions: Gly (-20), Phe (-12), Asp (+4), and Pro (+15); and (b) scintigraphically imaging the radiolabelled polypeptides.
Claim 3
Dependent Claim
21 words
A method according to claim 1, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position +12.
Claim 4
Dependent Claim
21 words
A method according to claim 1, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -31.
Claim 5
Dependent Claim
21 words
A method according to claim 3, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -36.
Claim 6
Dependent Claim
21 words
A method according to claim 4, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -37.
Claim 7
Dependent Claim
21 words
A method according to claim 5, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -47.
Claim 8
Dependent Claim
21 words
A method according to claim 6, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -49.
Claim 9
Dependent Claim
21 words
A method according to claim 7, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -60.
Claim 10
Dependent Claim
21 words
A method according to claim 5, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -41.
Claim 11
Dependent Claim
21 words
A method according to claim 9, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -47.
Claim 12
Dependent Claim
21 words
A method according to claim 10, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -49.
Claim 13
Dependent Claim
21 words
A method according to claim 11, wherein said radiolabelled polypeptide further comprises a cysteine amino acid residue occurring at position -60.
Claim 14
Dependent Claim
18 words
A method according to claim 12, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:1.
Claim 15
Dependent Claim
18 words
A method according to claim 13, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:2.
Claim 16
Dependent Claim
18 words
A method according to claim 12, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:3.
Claim 17
Dependent Claim
18 words
A method according to claim 12, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:4.
Claim 18
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:5.
Claim 19
Dependent Claim
18 words
A method according to claim 1, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:6.
Claim 20
Dependent Claim
18 words
A method according to claim 1, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:7.
Claim 21
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:8.
Claim 22
Dependent Claim
18 words
A method according to claim 5, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:9.
Claim 23
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:10.
Claim 24
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:11.
Claim 25
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:12.
Claim 26
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:13.
Claim 27
Dependent Claim
18 words
A method according to claim 7, wherein the radiolabelled polypeptide has the amino acid sequence SEQ ID NO:14.
Claim 28
Dependent Claim
14 words
A method according to claim 1 wherein said scintigraphically imaging comprises imaging pulmonary emboli.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-01-09 | 1998-07-11 | 1999-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-01-09 | 2002-07-11 | 2003-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-01-09 | 2006-07-11 | 2007-01-10 | $7700.00 | Window Closed / Lapsed |